FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/09/095126 [Registered on: 19/09/2025] Trial Registered Prospectively
Last Modified On: 19/09/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   MITOCHONDRIAL SUPPLEMENTATION IMPACT ON RESOLUTION OF PEDIATRIC SEPTIC SHOCK 
Scientific Title of Study   IMPACT OF MITOCHONDRIAL SUPPLEMENTATION ON RESOLUTION OF PEDIATRIC SEPTIC SHOCK: A PROSPECTIVE RANDOMIZED CONTROL TRIAL 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Srijan Sinha 
Designation  Senior Resident (ACADEMIC) 
Affiliation  AIIMS RISHIKESH 
Address  PICU, Department of Pediatrics, AIIMS RISHIKESH, VIRBHADRA ROAD, RISHIKESH, DEHRADUN, UK 249203

Dehradun
UTTARANCHAL
249203
India 
Phone  9546884678  
Fax    
Email  AIIMSJ15@GMAIL.COM  
 
Details of Contact Person
Scientific Query
 
Name  Lokesh Tiwari 
Designation  Professor 
Affiliation  AIIMS RISHIKESH 
Address  PICU, Department of Pediatrics, AIIMS RISHIKESH, VIRBHADRA ROAD, RISHIKESH, DEHRADUN, UK 249203

Dehradun
UTTARANCHAL
249203
India 
Phone  9631638095  
Fax    
Email  LOKESHDOC@YAHOO.COM  
 
Details of Contact Person
Public Query
 
Name  Srijan Sinha 
Designation  Senior Resident 
Affiliation  AIIMS RISHIKESH 
Address  PICU, Department of Pediatrics, AIIMS RISHIKESH, VIRBHADRA ROAD, RISHIKESH, DEHRADUN, UK 249203

Dehradun
UTTARANCHAL
249203
India 
Phone  9546884678  
Fax    
Email  AIIMSJ15@GMAIL.COM  
 
Source of Monetary or Material Support  
AIIMS Rishikesh 
 
Primary Sponsor  
Name  AIIMS RISHIKESH 
Address  AIIMS RISHIKESH, VIRBHADRA ROAD, RISHIKESH, DEHRADUN DISTRICT, UTTARAKHAND, INDIA. 249203 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
DR SRIJAN SINHA  AIIMS RISHIKESH  PICU, Department of Pediatrics, AIIMS RISHIKESH, VIRBHADRA ROAD, RISHIKESH, UK
Dehradun
UTTARANCHAL 
9546884678

SRIJANSINHA2@GMAIL.COM 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
AIIMS RISHIKESH  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: R652||Severe sepsis,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Mitochondrial Supplementation  Thiamin Vitamin C Vitamin E Carnitine Coenzyme Q Hydrocortisone 
Comparator Agent  NIL  NIL 
 
Inclusion Criteria  
Age From  1.00 Month(s)
Age To  18.00 Year(s)
Gender  Both 
Details  Children aged 1 months to 18 years with septic shock, defined as children with suspect or confirmed sepsis and cardiovascular dysfunction as per Phoenix Sepsis Score 
 
ExclusionCriteria 
Details  Children who require Nil per oral status
Children with known HIV/HbSAg/HCV positive status
Children with confirmed Immunodeficiency
Children with malignancy
Children who are known cases of G6PD deficiency/ Oxalate nephropathy
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Comparison on median VIS score (Vasoactive inotrope score) during 1st 3 days after initiation of therapy.  Comparison on median VIS score (Vasoactive inotrope score) during 1st 3 days after initiation of therapy. 
 
Secondary Outcome  
Outcome  TimePoints 
Survival status at Day 3, Day 7, and Day 28 following initiation of mitochondrial supplementation in pediatric patients with septic shock.
Maximum vasoactive-inotropic score (VIS) on Days 5 and 7
Trend in Pediatric Sequential Organ Failure Assessment (pSOFA) scores from admission through Day 7 or until PICU discharge, whichever occurs earlier.
Ventilation-free days and Inotrope-free days within the first 28 days. 
3, 7, 28 DAYS 
 
Target Sample Size   Total Sample Size="160"
Sample Size from India="160" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   01/12/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - All of the individual participant data collected during the trial, after de-identification.

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Informed Consent Form
    Response - Clinical Study Report
    Response -  Analytic Code

  3. Who will be able to view these files?
    Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.

  4. For what types of analyses will this data be available?
    Response - For individual participant data meta-analysis.

  5. By what mechanism will data be made available?
    Response - Proposals should be directed to [SRIJANSINHA2@GMAIL.COM].

  6. For how long will this data be available start date provided 01-01-2028 and end date provided 31-12-2030?
    Response - Beginning 3 months and ending 5 years following article publication.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - NIL
Brief Summary  

Shock in children results from varied causes, hypovolemic and septic shock being the most common causes. Pediatric septic shock results due to inflammatory response to a focus of infection. In sepsis, there is release of various cytokines which results in increased capillary permeability and myocardial dysfunction. The early manifestations of shock in children include tachycardia, cold peripheries, prolonged CFT, narrow pulse pressure and late signs include altered mental status and hypotension. Early recognition of shock and early interventions are associated with favourable outcomes.

Metabolic supplementation refers to a therapeutic strategy aimed at correcting the underlying metabolic derangements that occur during critical illness, particularly in conditions such as sepsis, septic shock, multi-organ dysfunction, and acute kidney injury (AKI). During severe illness, multiple metabolic pathways become dysregulated, including impaired cellular energy production, mitochondrial dysfunction, oxidative stress, hormonal disturbances, and dysregulated immune responses. These disturbances can further perpetuate organ dysfunction, making targeted metabolic support an important adjunct to conventional resuscitation strategies. The cornerstone of metabolic resuscitation involves the administration of key micronutrients and metabolic cofactors that support mitochondrial function, reduce oxidative stress, and modulate inflammation. One of the most studied regimens is the combination of intravenous Vitamin C, hydrocortisone, and thiamine. Vitamin C acts as a potent antioxidant and cofactor for catecholamine synthesis; thiamine supports mitochondrial oxidative metabolism and prevents lactic acidosis; while hydrocortisone helps restore vascular responsiveness and modulate the exaggerated inflammatory response.


Mitochondrial supplementation represents an emerging therapeutic approach aimed at restoring mitochondrial function in critically ill patients, where mitochondrial dysfunction is increasingly recognized as a central contributor to multi-organ failure. Mitochondria play a pivotal role in energy production, regulation of oxidative stress, calcium homeostasis, and apoptosis. In conditions such as sepsis, ischemia-reperfusion injury, acute kidney injury, cardiac arrest, and neurodegenerative disorders, mitochondrial injury leads to impaired oxidative phosphorylation, excessive generation of reactive oxygen species (ROS), mitochondrial membrane permeability transition pore (mPTP) opening, calcium dysregulation, and activation of intrinsic apoptotic pathways. These processes collectively result in bioenergetic failure, cellular dysfunction, and organ injury. Therapeutic strategies for mitochondrial supplementation include the administration of systemic and mitochondria-targeted antioxidants and metabolic cofactors (e.g., Coenzyme Q10, L-carnitine) and agents that stimulate mitochondrial biogenesis. Given the central role of impaired perfusion, systemic inflammation, and metabolic dysregulation in pediatric shock and AKI, there is a growing interest in adjunctive therapies targeting mitochondrial health and cellular energetics. This trial aims to explore its role in pediatric septic shock as an adjunct to standard of care.

 
Close